Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Health Canada has approved MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults with NYHA class II-III symptoms. This is the fifth regulatory approval for aficamten in less than a year, following approvals by the FDA and China NMPA in December 2025 and by the European Commission and UK MHRA earlier in 2026. The Canadian authorization is supported by the pivotal Phase 3 SEQUOIA-HCM trial, which showed a statistically significant improvement in peak oxygen uptake (LSM difference 1.74 mL/kg/min; p=0.000002) and a well-tolerated profile.
Key figures
- Drug Name
- MYQORZO (aficamten)
- Phase Of Trial
- Phase 3
- Approvals count
- fifth regulatory approval for MYQORZO in less than a year
- Pvo2 lsm difference
- 1.74 mL/kg/min [1.04 - 2.44]; p=0.000002
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.